404 related articles for article (PubMed ID: 27250825)
21. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway.
Heeg MH; Koziolek MJ; Vasko R; Schaefer L; Sharma K; Müller GA; Strutz F
Kidney Int; 2005 Jul; 68(1):96-109. PubMed ID: 15954899
[TBL] [Abstract][Full Text] [Related]
22. Relaxin-like peptides in male reproduction - a human perspective.
Ivell R; Agoulnik AI; Anand-Ivell R
Br J Pharmacol; 2017 May; 174(10):990-1001. PubMed ID: 27933606
[TBL] [Abstract][Full Text] [Related]
23. Relaxin' the brain: a case for targeting the nucleus incertus network and relaxin-3/RXFP3 system in neuropsychiatric disorders.
Kumar JR; Rajkumar R; Jayakody T; Marwari S; Hong JM; Ma S; Gundlach AL; Lai MKP; Dawe GS
Br J Pharmacol; 2017 May; 174(10):1061-1076. PubMed ID: 27597467
[TBL] [Abstract][Full Text] [Related]
24. Role of protein kinase C β₂ in relaxin-mediated inhibition of cardiac fibrosis.
Su W; Wang P; Chen H; Li H
J Endocrinol Invest; 2014 Jun; 37(6):559-64. PubMed ID: 24729283
[TBL] [Abstract][Full Text] [Related]
25. Distribution, physiology and pharmacology of relaxin-3/RXFP3 systems in brain.
Ma S; Smith CM; Blasiak A; Gundlach AL
Br J Pharmacol; 2017 May; 174(10):1034-1048. PubMed ID: 27774604
[TBL] [Abstract][Full Text] [Related]
26. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo.
Samuel CS; Unemori EN; Mookerjee I; Bathgate RA; Layfield SL; Mak J; Tregear GW; Du XJ
Endocrinology; 2004 Sep; 145(9):4125-33. PubMed ID: 15155573
[TBL] [Abstract][Full Text] [Related]
27. Generation of a multi-functional, target organ-specific, anti-fibrotic molecule by molecular engineering of the extracellular matrix protein, decorin.
Järvinen TAH; Ruoslahti E
Br J Pharmacol; 2019 Jan; 176(1):16-25. PubMed ID: 29847688
[TBL] [Abstract][Full Text] [Related]
28. Relaxin's induction of metalloproteinases is associated with the loss of collagen and glycosaminoglycans in synovial joint fibrocartilaginous explants.
Naqvi T; Duong TT; Hashem G; Shiga M; Zhang Q; Kapila S
Arthritis Res Ther; 2005; 7(1):R1-11. PubMed ID: 15642129
[TBL] [Abstract][Full Text] [Related]
29. H3 relaxin demonstrates antifibrotic properties via the RXFP1 receptor.
Hossain MA; Man BC; Zhao C; Xu Q; Du XJ; Wade JD; Samuel CS
Biochemistry; 2011 Mar; 50(8):1368-75. PubMed ID: 21229994
[TBL] [Abstract][Full Text] [Related]
30. Relaxin: an endogenous renoprotective factor?
Hewitson TD; Samuel CS
Ann N Y Acad Sci; 2009 Apr; 1160():289-93. PubMed ID: 19416206
[TBL] [Abstract][Full Text] [Related]
31. Understanding relaxin signalling at the cellular level.
Valkovic AL; Bathgate RA; Samuel CS; Kocan M
Mol Cell Endocrinol; 2019 May; 487():24-33. PubMed ID: 30592984
[TBL] [Abstract][Full Text] [Related]
32. Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites.
Unemori EN; Lewis M; Constant J; Arnold G; Grove BH; Normand J; Deshpande U; Salles A; Pickford LB; Erikson ME; Hunt TK; Huang X
Wound Repair Regen; 2000; 8(5):361-70. PubMed ID: 11186125
[TBL] [Abstract][Full Text] [Related]
33. Relaxin in cardiovascular and renal disease.
Samuel CS; Hewitson TD
Kidney Int; 2006 May; 69(9):1498-502. PubMed ID: 16672919
[TBL] [Abstract][Full Text] [Related]
34. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis.
Chow BS; Kocan M; Bosnyak S; Sarwar M; Wigg B; Jones ES; Widdop RE; Summers RJ; Bathgate RA; Hewitson TD; Samuel CS
Kidney Int; 2014 Jul; 86(1):75-85. PubMed ID: 24429402
[TBL] [Abstract][Full Text] [Related]
35. Relaxin and its role in the development and treatment of fibrosis.
Bennett RG
Transl Res; 2009 Jul; 154(1):1-6. PubMed ID: 19524867
[TBL] [Abstract][Full Text] [Related]
36. The effect of relaxin treatment on skeletal muscle injuries.
Negishi S; Li Y; Usas A; Fu FH; Huard J
Am J Sports Med; 2005 Dec; 33(12):1816-24. PubMed ID: 16157846
[TBL] [Abstract][Full Text] [Related]
37. The relaxin family peptide receptor 1 (RXFP1): An emerging player in human health and disease.
Chen TY; Li X; Hung CH; Bahudhanapati H; Tan J; Kass DJ; Zhang Y
Mol Genet Genomic Med; 2020 Apr; 8(4):e1194. PubMed ID: 32100955
[TBL] [Abstract][Full Text] [Related]
38. Relaxin remodels fibrotic healing following myocardial infarction.
Samuel CS; Cendrawan S; Gao XM; Ming Z; Zhao C; Kiriazis H; Xu Q; Tregear GW; Bathgate RA; Du XJ
Lab Invest; 2011 May; 91(5):675-90. PubMed ID: 21221074
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic potential of NADPH oxidase 1/4 inhibitors.
Teixeira G; Szyndralewiez C; Molango S; Carnesecchi S; Heitz F; Wiesel P; Wood JM
Br J Pharmacol; 2017 Jun; 174(12):1647-1669. PubMed ID: 27273790
[TBL] [Abstract][Full Text] [Related]
40. Investigations into the inhibitory effects of relaxin on renal myofibroblast differentiation.
Samuel CS; Mookerjee I; Halls ML; Summers RJ; Chew E; Bathgate RA; Tregear GW; Hewitson TD
Ann N Y Acad Sci; 2009 Apr; 1160():294-9. PubMed ID: 19416207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
